Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Cellular mechanotransduction, a critical regulator of numerous biological processes, is the
conversion from mechanical signals to biochemical signals regarding cell activities and …
conversion from mechanical signals to biochemical signals regarding cell activities and …
Therapeutic DNAzymes: from structure design to clinical applications
Therapeutic DNAzymes have unceasingly intrigued the scientific community owing to their
prosperous gene regulation capability. The efficacy of DNAzymes against many types of …
prosperous gene regulation capability. The efficacy of DNAzymes against many types of …
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
AS Paller, EL Simpson, EC Siegfried, MJ Cork… - The Lancet, 2022 - thelancet.com
Background Current systemic treatments for children younger than 6 years with moderate-to-
severe atopic dermatitis that is uncontrolled with topical therapies might have suboptimal …
severe atopic dermatitis that is uncontrolled with topical therapies might have suboptimal …
Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic targets in atopic diseases
Type 2 inflammation is characterized by overexpression and heightened activity of type 2
cytokines, mediators and cells that drive neuroimmune activation and sensitization to …
cytokines, mediators and cells that drive neuroimmune activation and sensitization to …
The role of dendritic cells in allergic diseases
P Liu, C Kang, J Zhang, Y Liu, J Liu, T Hu… - International …, 2022 - Elsevier
Allergic diseases are important diseases that affect many patients worldwide. Over the past
few decades, the incidence of allergic diseases has increased significantly due to social …
few decades, the incidence of allergic diseases has increased significantly due to social …
IL-5 serum and appendicular lavage fluid concentrations correlate with eosinophilic infiltration in the appendicular wall supporting a role for a hypersensitivity type I …
N Carvalho, E Carolino, H Coelho, A Cóias… - International Journal of …, 2022 - mdpi.com
Appendicitis is the most common abdominal surgical emergency, but its aetiology is not fully
understood. We and others have proposed that allergic responses play significant roles in its …
understood. We and others have proposed that allergic responses play significant roles in its …
Dupilumab Treatment in Pediatric Patients Aged 6–11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review
Atopic dermatitis (AD) is the most common inflammatory skin disease in children. Children
with severe AD have a multidimensional disease burden characterized by skin lesions …
with severe AD have a multidimensional disease burden characterized by skin lesions …
Systemic inflammatory proteins in offspring following maternal probiotic supplementation for atopic dermatitis prevention
DP Zakiudin, ADB Rø, V Videm, T Øien… - Clinical and Molecular …, 2023 - Springer
Background Maternal probiotic supplementation has a promising effect on atopic dermatitis
(AD) prevention in infancy. In the randomised controlled study, Probiotics in the Prevention …
(AD) prevention in infancy. In the randomised controlled study, Probiotics in the Prevention …
Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis
AS Paller, A Pinter, L Wine Lee, R Aschoff, J Zdybski… - Advances in …, 2024 - Springer
Introduction Treatment options for children younger than 6 years with severe atopic
dermatitis (AD) are limited, as systemic immunosuppressants may present safety concerns …
dermatitis (AD) are limited, as systemic immunosuppressants may present safety concerns …
Dupilumab safety and efficacy in a Phase III open-label extension trial in children 6–11 years of age with severe atopic dermatitis
Background For children aged 6–11 years with uncontrolled severe atopic dermatitis (AD),
16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with …
16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with …